8th December 2016

Clinical milestone for ReNeuron

ReNeuron has achieved “the most important clinical milestone” in its history with the results of a recent trial.

They also announced “positive data” from its phase II clinical trial (PISCES II) of its CTX cell therapy candidate for stroke disability.

Olav Hellebø, ReNeuron’s chief executive, said: “Our therapeutic development programmes have progressed well during the period, culminating in today’s announcement of positive phase II data from the PISCES II clinical trial of our CTX cell therapy candidate for stroke disability.

“The results of this study represent the most important clinical milestone in ReNeuron’s history and enable us to progress the CTX treatment into advanced clinical development in this indication. The unmet medical need in chronic stroke disability is enormous and we are delighted that we are now one step closer to being able to offer an effective therapy to these patients.”

View ReNeuron’s profile here.